Activity: Talks and presentationsConference presentations


The main cause of morbidity and mortality in cystic fibrosis (CF) patients is bacterial airway infections, and to combat these infections the patients are treated with large amounts of antibiotics. Despite the treatments, however, the infections (in particular by Pseudomonas aeruginosa) persist. P. aeruginosa is inherently resistant to many antibiotics and develops multi-resistance over time, resulting in major limitations of antibiotic treatment possibilities. Therefore we propose the use of antibiotic “Collateral drug cycling” for treatment of both initial persistent infections as well as chronic infections with P. aeruginosa.
Period17 Mar 2016
Held atUnknown